Geron Corporation (GERN)
NASDAQ: GERNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GERN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $560.94M
- Forward P/E
- 9.67
- EPS (TTM)
- -$0.08
- Dividend yield
- None
- 52-week range
- 0.84 – 2.01
- Day range
- 0.8615 – 0.925
- Volume / Avg
- 13.83M / 13.05M
- Beta
- —
- Shares outstanding
- 644.24M
52-week range
GERN stock today
Geron (GERN) closed at $0.8707 on Nov 20, down 4.63% (-$0.0423), versus the S&P 500's 3.70% decline. At this level, GERN sits near the bottom of its 52-week range of $0.84 to $2.01: 56.7% below the high, set on Feb 19, 2026 and 3.7% above the low. GERN is down 34.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 22.3%.
Geron has posted a net loss over the last twelve months (EPS of -$0.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Geron
Company profileGeron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Harout Semerjian
- Headquarters
- Foster City, CA
- Employees
- 258
- IPO year
- 1996
- Website
- geron.com
Financial highlights
Full financialsGeron reported a net loss of $83.5 million, compared with a loss of $174.6 million a year earlier. Diluted earnings per share came in at -$0.13.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $237.00K | $596.00K | $1.39M |
| Growth | — | — | -60.23% | -57.21% | +450.59% |
| Net income | $-83.50M | $-174.57M | $-184.13M | $-141.90M | $-116.11M |
| EPS (diluted) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$3.50+301.98%
- Strong buy 1
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.00 vs $-0.01
- Surprise
- +100.00%
GERN news
All GERN news- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Geron: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Geron Corp (GERN) Q3 2026 Earnings Call TranscriptNasdaq
- Geron Corporation Reports Third Quarter 2026 Financial Results and Discontinues Phase 3 IMpactMF TrialNasdaqGERN, WSO.B
- Geron outlines $220M-$240M 2026 RYTELO net revenue outlook while initiating Germany launch by year-endSeeking Alpha
- Geron swings to profits in Q3 on strong Rytelo growthSeeking Alpha
- Geron Q3 RYTELO revenue rises 5% sequentially to $60.1M; lowers expense outlookSeeking Alpha
- Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
Geron peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs GERN |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs GERN |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs GERN |
| DSGNDesign Therapeutics Inc. | 9.02 | -3.22% | $577.61M | vs GERN |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs GERN |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs GERN |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs GERN |
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs GERN |
Indexes, lists and sector
Geron stock FAQ
What is Geron's stock price today?
GERN last traded at $0.8707 as of Nov 20, 4:00 PM EST, down 4.63% on the day. Prices are delayed at least 15 minutes.
Does Geron pay a dividend?
No. Geron does not currently pay a regular cash dividend.
Who is Geron's CEO?
Mr. Harout Semerjian is the chief executive officer of Geron Corporation, which has about 258 employees.
Has GERN ever split its stock?
Yes. The most recent GERN stock split was a 1058-for-1000 split on Jul 22, 2014.
What is the GERN 52-week high?
The 52-week high for GERN is $2.01 and the 52-week low is $0.84. The stock is currently 56.7% below its high.